Applications of PET imaging with the proliferation marker [18F]-FLT

M. Peck, H. A. Pollack, A. Friesen, M. Muzi, S. C. Shoner, E. G. Shankland, J. R. Fink, J. O. Armstrong, Jeanne Link, Kenneth Krohn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

[18F]-3'-fluoro-3'-deoxythymidine (FLT) is a nucleoside-analog imaging agent for quantifying cellular proliferation that was first reported in 1998. It accumulates during the S-phase of the cell cycle through the action of cytosolic thymidine kinase, TK1. Since TK1 is primarily expressed in dividing cells, FLT uptake is essentially limited to dividing cells. Thus FLT is an effective measure of cell proliferation. FLT uptake has been shown to correlate with the more classic proliferation marker, the monoclonal antibody to Ki-67. Increased cellular proliferation is known to correlate with worse outcome in many cancers. However, the Ki-67 binding assay is performed on a sampled preparation, ex vivo, whereas FLT can be quantitatively measured in vivo using positron emission tomography (PET). FLT is an effective and quantitative marker of cell proliferation, and therefore a useful prognostic predictor in the setting of neoplastic disease. This review summarizes clinical studies from 2011 forward that used FLT-PET to assess tumor response to therapy. The paper focuses on our recommendations for a standardized clinical trial protocol and components of a report so multi center studies can be effectively conducted, and different studies can be compared. For example, since FLT is glucuronidated by the liver, and the metabolite is not transported into the cell, the plasma fraction of FLT can be significantly changed by treatment with particular drugs that deplete this enzyme, including some chemotherapy agents and pain medications. Therefore, the plasma level of metabolites should be measured to assure FLT uptake kinetics can be accurately calculated. This is important because the flux constant (KFLT) is a more accurate measure of proliferation and, by inference, a better discriminator of tumor recurrence than standardized uptake value (SUVFLT). This will allow FLT imaging to be a specific and clinically relevant prognostic predictor in the treatment of neoplastic disease.

Original languageEnglish (US)
Pages (from-to)95-104
Number of pages10
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume59
Issue number1
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Cell Proliferation
Clinical Protocols
Neoplasms
Thymidine Kinase
Plasma Cells
S Phase
Nucleosides
Cell Cycle
Therapeutics
Monoclonal Antibodies
Clinical Trials
Recurrence
Drug Therapy
Pain
alovudine
Liver
Enzymes
Pharmaceutical Preparations

Keywords

  • Biological markers
  • Cell proliferation
  • Diagnostic imaging
  • Dideoxynucleosides
  • Pharmacology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Peck, M., Pollack, H. A., Friesen, A., Muzi, M., Shoner, S. C., Shankland, E. G., ... Krohn, K. (2015). Applications of PET imaging with the proliferation marker [18F]-FLT. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 59(1), 95-104.

Applications of PET imaging with the proliferation marker [18F]-FLT. / Peck, M.; Pollack, H. A.; Friesen, A.; Muzi, M.; Shoner, S. C.; Shankland, E. G.; Fink, J. R.; Armstrong, J. O.; Link, Jeanne; Krohn, Kenneth.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 59, No. 1, 01.03.2015, p. 95-104.

Research output: Contribution to journalArticle

Peck, M, Pollack, HA, Friesen, A, Muzi, M, Shoner, SC, Shankland, EG, Fink, JR, Armstrong, JO, Link, J & Krohn, K 2015, 'Applications of PET imaging with the proliferation marker [18F]-FLT', Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 59, no. 1, pp. 95-104.
Peck M, Pollack HA, Friesen A, Muzi M, Shoner SC, Shankland EG et al. Applications of PET imaging with the proliferation marker [18F]-FLT. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2015 Mar 1;59(1):95-104.
Peck, M. ; Pollack, H. A. ; Friesen, A. ; Muzi, M. ; Shoner, S. C. ; Shankland, E. G. ; Fink, J. R. ; Armstrong, J. O. ; Link, Jeanne ; Krohn, Kenneth. / Applications of PET imaging with the proliferation marker [18F]-FLT. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2015 ; Vol. 59, No. 1. pp. 95-104.
@article{a4179bab61454a6abec1bbe8cd77823c,
title = "Applications of PET imaging with the proliferation marker [18F]-FLT",
abstract = "[18F]-3'-fluoro-3'-deoxythymidine (FLT) is a nucleoside-analog imaging agent for quantifying cellular proliferation that was first reported in 1998. It accumulates during the S-phase of the cell cycle through the action of cytosolic thymidine kinase, TK1. Since TK1 is primarily expressed in dividing cells, FLT uptake is essentially limited to dividing cells. Thus FLT is an effective measure of cell proliferation. FLT uptake has been shown to correlate with the more classic proliferation marker, the monoclonal antibody to Ki-67. Increased cellular proliferation is known to correlate with worse outcome in many cancers. However, the Ki-67 binding assay is performed on a sampled preparation, ex vivo, whereas FLT can be quantitatively measured in vivo using positron emission tomography (PET). FLT is an effective and quantitative marker of cell proliferation, and therefore a useful prognostic predictor in the setting of neoplastic disease. This review summarizes clinical studies from 2011 forward that used FLT-PET to assess tumor response to therapy. The paper focuses on our recommendations for a standardized clinical trial protocol and components of a report so multi center studies can be effectively conducted, and different studies can be compared. For example, since FLT is glucuronidated by the liver, and the metabolite is not transported into the cell, the plasma fraction of FLT can be significantly changed by treatment with particular drugs that deplete this enzyme, including some chemotherapy agents and pain medications. Therefore, the plasma level of metabolites should be measured to assure FLT uptake kinetics can be accurately calculated. This is important because the flux constant (KFLT) is a more accurate measure of proliferation and, by inference, a better discriminator of tumor recurrence than standardized uptake value (SUVFLT). This will allow FLT imaging to be a specific and clinically relevant prognostic predictor in the treatment of neoplastic disease.",
keywords = "Biological markers, Cell proliferation, Diagnostic imaging, Dideoxynucleosides, Pharmacology",
author = "M. Peck and Pollack, {H. A.} and A. Friesen and M. Muzi and Shoner, {S. C.} and Shankland, {E. G.} and Fink, {J. R.} and Armstrong, {J. O.} and Jeanne Link and Kenneth Krohn",
year = "2015",
month = "3",
day = "1",
language = "English (US)",
volume = "59",
pages = "95--104",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Applications of PET imaging with the proliferation marker [18F]-FLT

AU - Peck, M.

AU - Pollack, H. A.

AU - Friesen, A.

AU - Muzi, M.

AU - Shoner, S. C.

AU - Shankland, E. G.

AU - Fink, J. R.

AU - Armstrong, J. O.

AU - Link, Jeanne

AU - Krohn, Kenneth

PY - 2015/3/1

Y1 - 2015/3/1

N2 - [18F]-3'-fluoro-3'-deoxythymidine (FLT) is a nucleoside-analog imaging agent for quantifying cellular proliferation that was first reported in 1998. It accumulates during the S-phase of the cell cycle through the action of cytosolic thymidine kinase, TK1. Since TK1 is primarily expressed in dividing cells, FLT uptake is essentially limited to dividing cells. Thus FLT is an effective measure of cell proliferation. FLT uptake has been shown to correlate with the more classic proliferation marker, the monoclonal antibody to Ki-67. Increased cellular proliferation is known to correlate with worse outcome in many cancers. However, the Ki-67 binding assay is performed on a sampled preparation, ex vivo, whereas FLT can be quantitatively measured in vivo using positron emission tomography (PET). FLT is an effective and quantitative marker of cell proliferation, and therefore a useful prognostic predictor in the setting of neoplastic disease. This review summarizes clinical studies from 2011 forward that used FLT-PET to assess tumor response to therapy. The paper focuses on our recommendations for a standardized clinical trial protocol and components of a report so multi center studies can be effectively conducted, and different studies can be compared. For example, since FLT is glucuronidated by the liver, and the metabolite is not transported into the cell, the plasma fraction of FLT can be significantly changed by treatment with particular drugs that deplete this enzyme, including some chemotherapy agents and pain medications. Therefore, the plasma level of metabolites should be measured to assure FLT uptake kinetics can be accurately calculated. This is important because the flux constant (KFLT) is a more accurate measure of proliferation and, by inference, a better discriminator of tumor recurrence than standardized uptake value (SUVFLT). This will allow FLT imaging to be a specific and clinically relevant prognostic predictor in the treatment of neoplastic disease.

AB - [18F]-3'-fluoro-3'-deoxythymidine (FLT) is a nucleoside-analog imaging agent for quantifying cellular proliferation that was first reported in 1998. It accumulates during the S-phase of the cell cycle through the action of cytosolic thymidine kinase, TK1. Since TK1 is primarily expressed in dividing cells, FLT uptake is essentially limited to dividing cells. Thus FLT is an effective measure of cell proliferation. FLT uptake has been shown to correlate with the more classic proliferation marker, the monoclonal antibody to Ki-67. Increased cellular proliferation is known to correlate with worse outcome in many cancers. However, the Ki-67 binding assay is performed on a sampled preparation, ex vivo, whereas FLT can be quantitatively measured in vivo using positron emission tomography (PET). FLT is an effective and quantitative marker of cell proliferation, and therefore a useful prognostic predictor in the setting of neoplastic disease. This review summarizes clinical studies from 2011 forward that used FLT-PET to assess tumor response to therapy. The paper focuses on our recommendations for a standardized clinical trial protocol and components of a report so multi center studies can be effectively conducted, and different studies can be compared. For example, since FLT is glucuronidated by the liver, and the metabolite is not transported into the cell, the plasma fraction of FLT can be significantly changed by treatment with particular drugs that deplete this enzyme, including some chemotherapy agents and pain medications. Therefore, the plasma level of metabolites should be measured to assure FLT uptake kinetics can be accurately calculated. This is important because the flux constant (KFLT) is a more accurate measure of proliferation and, by inference, a better discriminator of tumor recurrence than standardized uptake value (SUVFLT). This will allow FLT imaging to be a specific and clinically relevant prognostic predictor in the treatment of neoplastic disease.

KW - Biological markers

KW - Cell proliferation

KW - Diagnostic imaging

KW - Dideoxynucleosides

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=84943192581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943192581&partnerID=8YFLogxK

M3 - Article

C2 - 25737423

AN - SCOPUS:84943192581

VL - 59

SP - 95

EP - 104

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -